RHYTHM PHARMACEUTICALS, INC.

For the period ended Mar 31, 2026. Filed May 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

RYTM$113.95+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	Three months ended March 31,
	2026	2025
Revenues:
Product revenue, net	$60,112	$37,718
License revenue	—	(5,014)
Total revenues	60,112	32,704
Costs and expenses:
Cost of sales	7,157	3,648
Research and development	41,725	36,973
Selling, general, and administrative	63,591	39,087
Total costs and expenses	112,473	79,708
Loss from operations	(52,361)	(47,004)
Other income (expense):
Other income (expense), net	(1,704)	(644)
Interest expense	(4,583)	(5,409)
Interest income	3,554	3,639
Total other income (expense), net	(2,733)	(2,414)
Loss before income taxes	(55,094)	(49,418)
Provision for income taxes	545	80
Net loss	$(55,639)	$(49,498)
Accrued dividends on convertible preferred stock	(1,104)	(1,322)
Net loss attributable to common stockholders	$(56,743)	$(50,820)
Net loss per share attributable to common stockholders, basic and diluted	$(0.83)	$(0.81)
Weighted-average common shares outstanding, basic and diluted	67,974,193	63,059,165
Net loss	$(55,639)	$(50,820)
Other comprehensive income (loss):
Foreign currency translation adjustment	1,784	(2)
Unrealized gain (loss), net on marketable securities	$(544)	(10)
Comprehensive loss	$(54,399)	$(50,832)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.